What is Agios Pharmaceuticals's remainder of fiscal 2026?

Agios Pharmaceuticals (AGIO) reported remainder of fiscal 2026 of $290K in Q1 2026.

How has Agios Pharmaceuticals's remainder of fiscal 2026 changed year-over-year?

Agios Pharmaceuticals's remainder of fiscal 2026 decreased by 11.3% year-over-year, from $327K to $290K.

Agios Pharmaceuticals AGIO Remainder of fiscal 2026

Other financials

Income statement

See full

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Balance sheet

See full

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Valuation

See full

Market cap$2.16B+18.1%

Enterprise value$2.08B+15.2%

P/S32.7×-16.7×

Profitability

See full

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Returns & leverage

See full

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's remainder of fiscal 2026.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Agios Pharmaceuticals's remainder of fiscal 2026?: Agios Pharmaceuticals (AGIO) reported remainder of fiscal 2026 of $290K in Q1 2026.
How has Agios Pharmaceuticals's remainder of fiscal 2026 changed year-over-year?: Agios Pharmaceuticals's remainder of fiscal 2026 decreased by 11.3% year-over-year, from $327K to $290K.